Current and emerging maintenance therapies for ulcerative colitis

References

• Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011;140:1785-94
   PubMed Web of Science ®Google Scholar
• Ghosh S, Mitchell R. Results of the European Federation of Crohn’s and Colitis Associations (EFCCA) patient survey: prevalence and impact on quality of life. Gut 2006;55:A72
   Google Scholar
• Travis SP, Higgins PD, Orchard T, et al. Review article: defining remission in ulcerative colitis. Aliment Pharmacol Ther 2011;34(2):113-24
   PubMed Web of Science ®Google Scholar
• Rosenberg L, Nanda KS, Zenlea T, et al. Histologic markers of inflammation in patients with ulcerative colitis in clinical remission. Clin Gastroenterol Hepatol 2013;11(8):991-6
   PubMedGoogle Scholar
• Rosenberg L, Lawlor GO, Zenlea T, et al. Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission. Inflamm Bowel Dis 2013;19(4):779-84
   PubMed Web of Science ®Google Scholar
• Dissanayake AS, Truelove SC. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin). Gut 1973;14(12):923-6
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sninsky CA, Robinson M, et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group. Ann Intern Med 1996;124(2):204-11
   PubMedGoogle Scholar
• Miner P, Hanauer S, Robinson M, et al. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. Dig Dis Sci 1995;40(2):296-304
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Gordon GL, Zakko S, et al. Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis - a 6-month placebo-controlled trial. Aliment Pharmacol Ther 2010;32(8):990-9
   PubMed Web of Science ®Google Scholar
• D’Haens G, Sandborn WJ, Barrett K, et al. Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis. Am J Gastroenterol 2012;107(7):1064-77
   PubMedGoogle Scholar
• Green JR, Gibson JA, Kerr GD, et al. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group. Aliment Pharmacol Ther 1998;12(12):1207-16
   PubMedGoogle Scholar
• Nielsen OH. Sulfasalazine intolerance. A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease. Scand J Gastroenterol 1982;17:389-93
   PubMed Web of Science ®Google Scholar
• Ford AC, Achkar JP, Khan KJ, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2011;106(4):601-16
   PubMed Web of Science ®Google Scholar
• Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012;10:CD000544
   PubMedGoogle Scholar
• Green JR, Lobo AJ, Holdsworth CD, et al. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. Gastroenterology 1998;114:15-22
   PubMed Web of Science ®Google Scholar
• Levine DS, Riff DS, Pruitt R, et al. A randomized, double blind, dose-response comparison of balsalazide (6.75 g),balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002;97(6):1398-407
   PubMedGoogle Scholar
• Pruitt R, Hanson J, Safdi M, et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002;97(12):3078-86
   PubMedGoogle Scholar
• Farrell RJ, Peppercorn MA. Equimolar doses of balsalazide and mesalamine: are we comparing apples and oranges? Am J Gastroenterol 2002;97(6):1283-5
   PubMedGoogle Scholar
• Kane S, Katz S, Jamal MM, et al. Strategies in maintenance for patients receiving long-term therapy (SIMPLE): a study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis. Inflamm Bowel Dis 2012;18(6):1026-33
   PubMedGoogle Scholar
• Prantera C, Kohn A, Campieri M, et al. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX® with Asacol®. Aliment Pharmacol Ther 2009;30(9):908-18
   PubMedGoogle Scholar
• Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Randomised trial of once-or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 2008;57(7):893-902
   PubMedGoogle Scholar
• Ford AC, Khan KJ, Sandborn WJ, et al. Once-daily dosing vs conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2011;106(12):2070-7
   PubMed Web of Science ®Google Scholar
• Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000;95(5):1263-76
   PubMed Web of Science ®Google Scholar
• d’Albasio G, Pacini F, Camarri E, et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol 1997;92(7):1143-7
   PubMed Web of Science ®Google Scholar
• Yokoyama H, Takagi S, Kuriyama S, et al. Eff ect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study. Inflamm Bowel Dis 2007;13:1115-20
   PubMed Web of Science ®Google Scholar
• Frieri G, Pimpo M, Galletti B, et al. Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis. Dig Liver Dis 2005;37(2):92-6
   PubMedGoogle Scholar
• Paoluzi P, d’Albasio G, Pera A, et al. Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one-year randomised multicentre trial. Dig Liver Dis 2002;34(11):787-93
   PubMedGoogle Scholar
• Ford AC, Khan KJ, Achkar JP, Moayyedi P. Efficacy of oral vs topical, or combined oral and topical 5-aminosalicylates, in Ulcerative Colitis: systematic review and meta-analysis. Am J Gastroenterol 2012;107(2):167-76
   PubMed Web of Science ®Google Scholar
• Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: an interim report on a controlled therapeutic trial. Br Med J 1974;1(5802):709-12
   Google Scholar
• Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006;55:47-53
   PubMed Web of Science ®Google Scholar
• Mate-Jimenez J, Hermida C, Cantero-Perona J, Moreno-Otero R. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000;12(11):1227-33
   PubMed Web of Science ®Google Scholar
• Sood A, Kaushal V, Midha V, et al. The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis. J Gastroenterol 2002;37(4):270-4
   PubMed Web of Science ®Google Scholar
• Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002;50:485-9
   PubMed Web of Science ®Google Scholar
• Adler DJ, Korelitz BI. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol 1990;85(6):717-22
   PubMed Web of Science ®Google Scholar
• George J, Present DH, Pou R, et al. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 1996;91(9):1711-14
   PubMedGoogle Scholar
• Fernández-Bañares F, Bertrán X, Esteve-Comas M, et al. Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Am J Gastroenterol 1996;91(12):2498-9
   PubMed Web of Science ®Google Scholar
• Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989;46(2):149-54
   PubMed Web of Science ®Google Scholar
• Gardiner SJ, Gearry RB, Begg EJ, et al. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold. Clin Gastroenterol Hepatol 2008;6(6):654-60
   PubMed Web of Science ®Google Scholar
• Gearry RB, Barclay ML, Burt MJ, et al. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol Drug Saf 2004;13(8):563-7
   PubMed Web of Science ®Google Scholar
• O’Connor A, Qasim A, O’Moráin CA. The long-term risk of continuous immunosuppression using thioguanides in inflammatory bowel disease. Ther Adv Chronic Dis 2010;1(1):7-16
   PubMedGoogle Scholar
• Gisbert JP, Linares PM, McNicholl AG, et al. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther 2009;30:126-37
   PubMed Web of Science ®Google Scholar
• Timmer A, McDonald JW, Tsoulis DJ, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012;9:CD000478
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353(23):2462-76
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009;137(4):1250-60
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Rutgeerts P, et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis 2012;18(2):201-11
   PubMed Web of Science ®Google Scholar
• Laharie D, Filippi J, Roblin X, et al. Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience. Aliment Pharmacol Ther 2013;37(10):998-1004
   PubMed Web of Science ®Google Scholar
• Rostholder E, Ahmed A, Cheifetz AS, Moss AC. Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis. Aliment Pharmacol Ther 2012;35(5):562-7
   PubMed Web of Science ®Google Scholar
• Paul S, Del Tedesco E, Marotte H, et al. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis 2013;19(12):2568-76
   PubMed Web of Science ®Google Scholar
• Panaccione R, Ghosh S, Middleton S, et al. Infliximab, azathioprine or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis. The UC SUCCESS trial. J Crohns Colitis 2011;140(5):S134
   Google Scholar
• Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014;146(2):392-400
   PubMed Web of Science ®Google Scholar
• Van Assche G, Magdelaine-Beuzelin C, D’Haens G, et al. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008;134:1861-8
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142(2):257-65; e1-3
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel JF, D’Haens G, et al. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther 2013;37(2):204-13
   PubMed Web of Science ®Google Scholar
• McDermott E, Murphy S, Keegan D, et al. Efficacy of Adalimumab as a long term maintenance therapy in ulcerative colitis. J Crohns Colitis 2013;7(2):150-3
   PubMed Web of Science ®Google Scholar
• Fasanmade AA, Adedokun OJ, Olson A, et al. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther 2010;48(5):297-308
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014;146(1):96-109
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369(8):699-710
   PubMed Web of Science ®Google Scholar
• Madsen K, Cornish A, Soper P, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001;121(3):580-91
   PubMed Web of Science ®Google Scholar
• Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999;13(8):1103-8
   PubMed Web of Science ®Google Scholar
• Miele E, Pascarella F, Giannetti E, et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 2009;104(2):437-43
   PubMed Web of Science ®Google Scholar
• Oren R, Arber N, Odes S, et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996;110(5):1416-21
   PubMed Web of Science ®Google Scholar
• Herrlinger KR, Cummings JR, Barnardo MC, et al. The pharmacogenetics of methotrexate in inflammatory bowel disease. Pharmacogenet Genomics 2005;15(10):705-11
   PubMed Web of Science ®Google Scholar
• Khan N, Abbas AM, Bazzano LA, et al. Long-term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-year retrospective cohort from the veterans affairs healthcare system. Aliment Pharmacol Ther 2012;36(8):755-64
   PubMed Web of Science ®Google Scholar
• Higgins PD, Rubin DT, Kaulback K, et al. Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther 2009;29(3):247-57
   PubMed Web of Science ®Google Scholar
• Hawthorne AB, Rubin G, Ghosh S. Review article: medication non-adherence in ulcerative colitis–strategies to improve adherence with mesalazine and other maintenance therapies. Aliment Pharmacol Ther 2008;27(12):1157-66
   PubMed Web of Science ®Google Scholar
• Moss AC, Beusterien K, Ahmed A, et al. Factors influencing adherence to mesalamine in patients with inflammatory bowel disease: a patient-reported qualitative analysis. Am J Gastroenterol 2011;106(S2):S442
   Web of Science ®Google Scholar
• Moss AC, Chaudhary N, Tukey M, et al. Impact of a patient-support program on mesalamine adherence in patients with ulcerative colitis – a prospective study. J Crohns Colitis 2010;4:171-5
   PubMed Web of Science ®Google Scholar
• Julsgaard M, Nørgaard M, Hvas CL, et al. Self-reported adherence to medical treatment prior to and during pregnancy among women with ulcerative colitis. Inflamm Bowel Dis 2011;17(7):1573-80
   PubMed Web of Science ®Google Scholar
• Gifford AE, Berg AH, Lahiff C, et al. A random urine test can identify patients at risk of mesalamine non-adherence: a prospective study. Am J Gastroenterol 2013;108(2):249-55
   PubMed Web of Science ®Google Scholar
• Kane S, Becker B, Harmsen WS, et al. Use of a screening tool to determine nonadherent behavior in inflammatory bowel disease. Am J Gastroenterol 2012;107(2):154-60
   PubMedGoogle Scholar
• Trindade AJ, Ehrlich A, Kornbluth A, Ullman TA. Are your patients taking their medicine? Validation of a new adherence scale in patients with inflammatory bowel disease and comparison with physician perception of adherence. Inflamm Bowel Dis 2011;17(2):599-604
   PubMed Web of Science ®Google Scholar
• Lopez A, Billioud V, Peyrin-Biroulet C, Peyrin-Biroulet L. Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review. Inflamm Bowel Dis 2013;19(7):1528-33
   PubMed Web of Science ®Google Scholar
• Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009;44(4):431-40
   PubMed Web of Science ®Google Scholar
• Hendriksen C, Kreiner S, Binder V. Long term prognosis in ulcerative colitis–based on results from a regional patient group from the county of Copenhagen. Gut 1985;26(2):158-63
   PubMedGoogle Scholar
• Kaplan GG, Seow CH, Ghosh S, et al. Decreasing colectomy rates for ulcerative colitis: a population-based time trend study. Am J Gastroenterol 2012;107(12):1879-87
   PubMed Web of Science ®Google Scholar
• Croft A, Walsh A, Doecke J, et al. Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs infliximab. Aliment Pharmacol Ther 2013;38(3):294-302
   PubMedGoogle Scholar
• Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526-35
   PubMed Web of Science ®Google Scholar
• Winther KV, Jess T, Langholz E, et al. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2004;2:1088-95
   PubMed Web of Science ®Google Scholar
• Jess T, Loftus EV, Velayos FS, et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology 2006;130:1039-46
   PubMed Web of Science ®Google Scholar
• Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004;126(2):451-9
   PubMed Web of Science ®Google Scholar
• Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005;100:1345-53
   PubMed Web of Science ®Google Scholar
• Rubin DT, Huo D, Kinnucan JA, et al. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol 2013;11(12):1601-8
   PubMed Web of Science ®Google Scholar
• Matula S, Croog V, Itzkowitz S, et al. Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. Clin Gastroenterol 2005;3:1015-21
   Google Scholar
• Gong J, Zhu L, Guo Z, et al. Use of thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel diseases: a meta-analysis. PLoS One 2013;8(11):e81487
   PubMed Web of Science ®Google Scholar
• Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007;133(4):1099-105
   PubMed Web of Science ®Google Scholar
• Rutter MD, Saunders BP, Wilkinson KH, et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 2004;53(12):1813-16
   PubMed Web of Science ®Google Scholar
• Yen EF, Kane SV, Ladabaum U. Cost-effectiveness of 5-aminosalicylic acid therapy for maintenance of remission in ulcerative colitis. Am J Gastroenterol 2008;103(12):3094-105
   PubMedGoogle Scholar
• Carter CT, Leher H, Smith P, et al. Impact of persistence with infliximab on hospitalizations in ulcerative colitis. Am J Manag Care 2011;17(6):385-92
   PubMedGoogle Scholar
• Buckland A, Bodger K. The cost-utility of high dose oral mesalazine for moderately active ulcerative colitis. Aliment Pharmacol Ther 2008;28(11-12):1287-96
   PubMed Web of Science ®Google Scholar
• rereton N, Bodger K, Kamm MA, et al. A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective. J Med Econ 2010;13(1):148-61
   PubMedGoogle Scholar